Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation

National Medical Journal of China

Volumn 85, Issue 7, 2005, Pages 444-447

  Gu, Wei Ying ^a   Chen, Zi Xing ^b   Hu, Shao Yan ^b   Zhu, Jiang ^b   Wang, Zhi Lin ^b   Yan, Feng ^b   Wang, Wei ^b   Cen, Jian Nong ^b   Shen, Hui Ling ^b   Qian, Jun ^b  

^a SOOCHOW UNIVERSITY   (China)

^b NONE

Author keywords

Bone marrow transplantation; Leukemia; Neoplasm, residual; Reverse transcription polymerase chain reaction

Indexed keywords

BCR ABL PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; RHO FACTOR; WT1 PROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANALYTICAL PARAMETERS; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC VALUE; FOLLOW UP; FUSION GENE; HUMAN; HUMAN TISSUE; LEUKEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANK SUM TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE SECTION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSPLANTATION, HOMOLOGOUS; WT1 PROTEINS;

EID: 20044364588     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Cazzaniga G, Rossi V, Biondi A. Monitoring minimal residual disease using chromosomal translocations in childhood acute lymphoblastic leukemia. Best Pract Res Clin Haematol, 2002,15: 21-35.
2. Szczepanski T, Flohr T, Van der Velden VH, et al. Molecular monitoring of residual disease using antigen receptor genes in childhhood acute lymphoblastic leukemia. Best Pract Res Clin Haematol, 2002,15: 37-57.
3. Crimwade D. The significance of minimal residual disease in pationts with t(15;17). Best Pract Res Clin Haematol, 2002,15: 137-158.
4. Liu Yin JA. Minimal residual disease in acute myeloid leukemia. Best Pract Res Clin Haematol, 2002,15: 119-135.
5. Menssen HD, Siehl JM, Thiel E. Wilms tumor gene (WT1) expression as a panleukemic marker. Int J Hematol, 2002, 76: 103-109.
6. Hosen N, Sonoda Y, Oji Y, et al. Very low frequencies of human normal CD34 + haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol, 2002, 116:409-420.
7. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia, 2003, 17: 1301-1312.
8. Yao L, Wang L, Wang W, et al. Expression of WT1 gene isoforms in acute leukemia patients. Chin J Hematol, 2002, 23:601-602.
9. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood, 2003, 101:1698-1704.
10. Cilloni D, Gottardi E, De Micheli D, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia, 2002, 16:2115-2121.
11. Trka J, Kalinova M, Hrusak O, et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia, 2002,16:1381-1389.